Guidance

Smallpox vaccine PGD template

PGD template for administering smallpox vaccine in response to mpox (monkeypox).

From:
UK Health Security Agency
Published
5 August 2022
Last updated
523 SeptemberAugust 20232024 — See all updates

Applies to England

Documents

Smallpox patient group direction (PGD) template

Ref: UKHSA gateway number GOV-15210

MS Word Document, 168 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Notice of extension of the validity of smallpox vaccine PGD

Ref: UKHSA gateway number GOV-15210

MS Word Document, 92.6 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of the smallpox vaccine, modified vacciniavaccina virus AnkaraAnkara-Bavarian - Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to mpox.

The smallpox PGD version 3.00 is valid from 15 September 2023 to 15 September 2024.

For2024 information:

  • at present, there are no stocks of the UK licensed MVA-BN vaccine Imvanex® available
  • Medicines and Healthcarehas productsbeen Regulatoryextended Agency (MHRA) granted batch-specific variation for batch number FDP00072 of the US licensed vaccine Jynneos® is the only batch allowed to be27 usedOctober under this PGD
2024.

Practitioners must not use this this PGD template template until it has been authorised in Section 2. This is a legal requirement (see (see Human Medicines Regulations 2012). Practitioners should follow local policypolicy/procedures or procedures to access authorised authorised PGD documents. documents.

This This PGD template template should be used with reference to current national recommendationguidance, on mpox vaccination, the the Green Book, andand Summary theof DirectProduct HealthcareCharacteristics for Professional Communication letter from Bavarian Nordic the differences between Imvanex® brand (licensed in UK) and Jynneos® brand (licensed in US) of live modified vaccinia virus Ankara.vaccine.

Updates to this page

Published 5 August 2022
Last updated 523 SeptemberAugust 20232024 + show all updates

  1. Added 'Notice of extension of the validity of smallpox vaccine PGD'.

  2. Added version 3 - see page 2 for change history.

  3. Added version 2.00 – details of changes on page 2 and updated batch information.

  4. Corrected review date.

Sign up for emails or print this page